EMA OKs Scil to make reteplase for Actavis
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has approved Scil Proteins' Halle, Germany facilities for manufacturing reteplase on behalf of Actavis, which markets the recombinant protein for the treatment of myocardial infarction as Rapilysin.